Viatris (VTRS) Net Cash Flow (2019 - 2026)
Viatris' (VTRS) quarterly Net Cash Flow came in at $461.9 million in Q1 2026, up 13485.29% year-on-year from N/an in Q1 2025, and up 25.45% quarter-over-quarter from $368.2 million in Q4 2025.
Viatris (VTRS) Net Cash Flow (2019 - 2026) Analysis & Trends
Viatris' Net Cash Flow history runs 8 years deep, the most recent figure standing at $461.9 million for Q1 2026.
- On a quarterly basis, Net Cash Flow rose 13485.29% year-over-year to $461.9 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 507.9% increase from a year earlier, with the FY2025 full-year figure at $594.3 million, up 362.04% from the prior year.
- Net Cash Flow improved to $461.9 million in Q1 2026 per VTRS's latest filing, from $368.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $937.7 million in Q3 2024 and bottomed at -$1.1 billion in Q4 2024.
- The 5-year median for Net Cash Flow is $34.7 million (2024), against an average of $68.1 million.
- Biggest YoY gain for Net Cash Flow was 14625.53% in 2023; the steepest drop was 1302.88% in 2023.
- Year by year, Net Cash Flow stood at $596.5 million in 2022, then tumbled by 155.47% to -$330.9 million in 2023, then plunged by 234.3% to -$1.1 billion in 2024, then surged by 133.29% to $368.2 million in 2025, then increased by 25.45% to $461.9 million in 2026.
- Per Business Quant, the three latest VTRS Net Cash Flow figures stand at $461.9 million (Q1 2026), $368.2 million (Q4 2025), and $417.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 15.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 461.90 Mn |
| Mar 31, 2026 | 461.90 Mn |
| Dec 31, 2025 | 368.20 Mn |
| Dec 31, 2025 | 368.20 Mn |
| Sep 30, 2025 | 417.90 Mn |
| Sep 30, 2025 | 417.90 Mn |
| Jun 30, 2025 | -195.20 Mn |
| Jun 30, 2025 | -195.20 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Dec 31, 2024 | -1.11 Bn |
| Dec 31, 2024 | -1.11 Bn |
| Sep 30, 2024 | 937.70 Mn |
| Sep 30, 2024 | 937.70 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | 34.70 Mn |
| Mar 31, 2024 | 34.70 Mn |
| Dec 31, 2023 | -330.90 Mn |
| Dec 31, 2023 | -330.90 Mn |